Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Broader sunshine bill in the works

This article was originally published in The Gray Sheet

Executive Summary

Physician Payments Sunshine Act remains a top priority for Sen. Herb Kohl, D-Wis., and his Special Committee on Aging. Co-sponsors already are discussing an expansion of the bill in light of recommendations from the Medicare Payment Advisory Commission, which called for a database to include device and drug firm payments not only to physicians, but also to academic medical centers, continuing medical education organizations and patient and physician advocacy groups (1"The Gray Sheet" Sept. 8, 2008, p. 9). A committee aide confirmed that continuing medical education providers are likely to be covered when the measure is reintroduced in 2009. The panel also will be monitoring marketing practices for Medicare Advantage plans in the next Congress; in August, CMS Acting Administrator Kerry Weems reported to Kohl that agency efforts to ensure compliance with its marketing guidelines have reduced violations, but continued oversight is necessary

You may also be interested in...



MedPAC Presents Policy Options For Reporting Physicians’ Ties To Industry

With legislation pending on public reporting of physicians' ties to industry, a group of independent advisors to Congress presented an early blueprint for a federal reporting system that could inform the final version of the bill

Teva Leapfrogs Mylan And Sandoz On Linaclotide

A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.

Tecentriq Disappoints In Post-Surgery Bladder Cancer

Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.
UsernamePublicRestriction

Register

MT026884

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel